Table 2.

Proportion of malignant lesions of each B3 subdiagnosis and comparison with the literature.

	ADH		FEA		LN		RS		PL		Proportion of B3		Overall PML for B3 lesions
	PML	n/N*	PML	n/N	PML	n/N	PML	n/N	PML	n/N	%	n	PML	n/N
This study (2012)	0.26	69/266	0.18	15/82	0.26	24/91	0.11	2/18	0.03	2/64	17.0%	1532/9153	0.21	112/521
Bianchi, 2011 (7)	0.27	197/721	0.12	31/245	0.22	83/377	0.10	14/132	0.13	18/135	11.9%	3107/26,165	0.21	349/1644
Dillon, 2007 (8)	0.35	14/40			0.40	4/9	0.17	9/54	0.18	5/28	5.7%	211/3729	0.21	37/177
El-Sayed, 2008 (9)	0.32	61/188			0.30	8/27	0.12	19/156	0.11	13/124	5.2%	705/13,452	0.2	106/523
Hayes, 2009 (10)	0.32	8/25	0.13	1/8	0.50	3/3	0.12	7/57	0.08	2/24	7.7%	141/1829	0.16	22/141
Houssami, 2007 (6)	0.45	63/141			0.61	14/23	0.17	7/42	0.23	10/44	9.2%	372/4035	0.3	98/279
Lee, 2003 (11)	0.46	13/28			0.66	6/9	0.20	5/25	0.15	3/20	3.0%	116/3822	0.3	29/96
Lieske, 2008 (12)	0.50	36/72	1.00	1/1	0.38	9/24	0.09	4/43	0.26	9/35	5.4%	220/4080	0.34	67/199
Noske, 2010 (13)	0.36	5/14	0.07	5/14	0.00	0/6	0.00	0/7	0.07	1/15	6.6%	122/1854	0.1	881

^*n/N = count of malignant lesions after open resection (n) from the total of B3 lesions in the histopathological subdiagnosis (N).

ADH, atypical ductal hyperplasia; FEA, flat epithelial atypia; LN, lobular neoplasia; PL, papillary lesion; PML, proportion of malignant lesions; RS, radial scar; VABB, vacuum-assisted breast biopsy.